197 related articles for article (PubMed ID: 34485908)
1. Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma.
Pratap UP; Sareddy GR; Liu Z; Venkata PP; Liu J; Tang W; Altwegg KA; Ebrahimi B; Li X; Tekmal RR; Viswanadhapalli S; McHardy S; Brenner AJ; Vadlamudi RK
Neurooncol Adv; 2021; 3(1):vdab099. PubMed ID: 34485908
[TBL] [Abstract][Full Text] [Related]
2. Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma.
Sareddy GR; Li X; Liu J; Viswanadhapalli S; Garcia L; Gruslova A; Cavazos D; Garcia M; Strom AM; Gustafsson JA; Tekmal RR; Brenner A; Vadlamudi RK
Sci Rep; 2016 Apr; 6():24185. PubMed ID: 27126081
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of KDM1A/LSD1 enhances estrogen receptor beta-mediated tumor suppression in ovarian cancer.
Venkata PP; Jayamohan S; He Y; Alejo S; Johnson JD; Palacios BE; Pratap UP; Chen Y; Liu Z; Zou Y; Lai Z; Suzuki T; Viswanadhapalli S; Weintraub ST; Palakurthi S; Valente PT; Tekmal RR; Kost ER; Vadlamudi RK; Sareddy GR
Cancer Lett; 2023 Oct; 575():216383. PubMed ID: 37714256
[TBL] [Abstract][Full Text] [Related]
4. Activation of estrogen receptor beta signaling reduces stemness of glioma stem cells.
Sareddy GR; Pratap UP; Venkata PP; Zhou M; Alejo S; Viswanadhapalli S; Tekmal RR; Brenner AJ; Vadlamudi RK
Stem Cells; 2021 May; 39(5):536-550. PubMed ID: 33470499
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Targeting of Ovarian Cancer Stem Cells Using Estrogen Receptor Beta Agonist.
He Y; Alejo S; Venkata PP; Johnson JD; Loeffel I; Pratap UP; Zou Y; Lai Z; Tekmal RR; Kost ER; Sareddy GR
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806169
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.
Zhou M; Sareddy GR; Li M; Liu J; Luo Y; Venkata PP; Viswanadhapalli S; Tekmal RR; Brenner A; Vadlamudi RK
Sci Rep; 2019 Apr; 9(1):6124. PubMed ID: 30992459
[TBL] [Abstract][Full Text] [Related]
7. Differential Effects of Estrogen Receptor β Isoforms on Glioblastoma Progression.
Liu J; Sareddy GR; Zhou M; Viswanadhapalli S; Li X; Lai Z; Tekmal RR; Brenner A; Vadlamudi RK
Cancer Res; 2018 Jun; 78(12):3176-3189. PubMed ID: 29661831
[TBL] [Abstract][Full Text] [Related]
8. Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer.
Datta J; Willingham N; Manouchehri JM; Schnell P; Sheth M; David JJ; Kassem M; Wilson TA; Radomska HS; Coss CC; Bennett CE; Ganju RK; Sardesai SD; Lustberg M; Ramaswamy B; Stover DG; Cherian MA
Front Oncol; 2022; 12():857590. PubMed ID: 35574319
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis.
Zhao L; Huang S; Mei S; Yang Z; Xu L; Zhou N; Yang Q; Shen Q; Wang W; Le X; Lau WB; Lau B; Wang X; Yi T; Zhao X; Wei Y; Warner M; Gustafsson JÅ; Zhou S
Proc Natl Acad Sci U S A; 2018 Apr; 115(16):E3673-E3681. PubMed ID: 29592953
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Development of Brain Permeable ERβ Agonist for the Treatment of Glioblastoma.
Pratap UP; Tidwell M; Balinda HU; Clanton NA; Yang X; Viswanadhapalli S; Sareddy GR; Liang D; Xie H; Chen Y; Lai Z; Tekmal RR; McHardy SF; Brenner AJ; Vadlamudi RK
Mol Cancer Ther; 2023 Nov; 22(11):1248-1260. PubMed ID: 37493258
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells.
Was H; Krol SK; Rotili D; Mai A; Wojtas B; Kaminska B; Maleszewska M
Clin Epigenetics; 2019 Jan; 11(1):11. PubMed ID: 30654849
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma.
Marampon F; Leoni F; Mancini A; Pietrantoni I; Codenotti S; Ferella L; Megiorni F; Porro G; Galbiati E; Pozzi P; Mascagni P; Budillon A; Maggio R; Tombolini V; Fanzani A; Gravina GL; Festuccia C
J Cancer Res Clin Oncol; 2019 Feb; 145(2):393-409. PubMed ID: 30474756
[TBL] [Abstract][Full Text] [Related]
13. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
Singh AK; Bishayee A; Pandey AK
Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma.
Lanzi C; Favini E; Dal Bo L; Tortoreto M; Arrighetti N; Zaffaroni N; Cassinelli G
J Exp Clin Cancer Res; 2021 Dec; 40(1):381. PubMed ID: 34857011
[TBL] [Abstract][Full Text] [Related]
15. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
Helland Ø; Popa M; Bischof K; Gjertsen BT; McCormack E; Bjørge L
PLoS One; 2016; 11(6):e0158208. PubMed ID: 27352023
[TBL] [Abstract][Full Text] [Related]
16. Enhanced efficacy of histone deacetylase inhibitor combined with bromodomain inhibitor in glioblastoma.
Meng W; Wang B; Mao W; Wang J; Zhao Y; Li Q; Zhang C; Tang Y; Ma J
J Exp Clin Cancer Res; 2018 Oct; 37(1):241. PubMed ID: 30285808
[TBL] [Abstract][Full Text] [Related]
17. The inhibitor of growth 1 (ING1) is involved in trichostatin A-induced apoptosis and caspase 3 signaling in p53-deficient glioblastoma cells.
Tamannai M; Farhangi S; Truss M; Sinn B; Wurm R; Bose P; Henze G; Riabowol K; von Deimling A; Tallen G
Oncol Res; 2010; 18(10):469-80. PubMed ID: 20681406
[TBL] [Abstract][Full Text] [Related]
18. Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma.
Meng W; Wang B; Mao W; Wang J; Zhao Y; Li Q; Zhang C; Ma J
Nagoya J Med Sci; 2019 Feb; 81(1):93-102. PubMed ID: 30962658
[TBL] [Abstract][Full Text] [Related]
19. BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma.
Gusyatiner O; Bady P; Pham MDT; Lei Y; Park J; Daniel RT; Delorenzi M; Hegi ME
Neuro Oncol; 2021 Oct; 23(10):1680-1692. PubMed ID: 33987681
[TBL] [Abstract][Full Text] [Related]
20. Different Susceptibilities of Human Melanoma Cell Lines to G2/M Blockage and Cell Death Activation in Response to the Estrogen Receptor β agonist LY500307.
Pontecorvi G; Bellenghi M; Tait S; Tirelli V; Matarrese P; Mattia G; Carè A; Puglisi R
J Cancer; 2022; 13(5):1573-1587. PubMed ID: 35371312
[No Abstract] [Full Text] [Related]
[Next] [New Search]
